These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 1573036)

  • 21. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response.
    Piscitelli SC; Frazier JA; McKenna K; Albus KE; Grothe DR; Gordon CT; Rapoport JL
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():94-7. PubMed ID: 7961584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Change in haloperidol level due to carbamazepine--a complicating factor in combined medication for schizophrenia.
    Kahn EM; Schulz SC; Perel JM; Alexander JE
    J Clin Psychopharmacol; 1990 Feb; 10(1):54-7. PubMed ID: 2106534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 24. Plasma haloperidol levels and clinical response.
    Smith RC
    Arch Gen Psychiatry; 1987 Dec; 44(12):1110-2. PubMed ID: 3689100
    [No Abstract]   [Full Text] [Related]  

  • 25. The Dose Reduction in Schizophrenia (DORIS) Study: a final report.
    Hirschowitz J; Hitzemann R; Piscani K; Burr G; Frecska E; Culliton D; Mann M; Curtis C
    Schizophr Res; 1997 Jan; 23(1):31-43. PubMed ID: 9050126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of repeated drug holidays on serum haloperidol concentrations, psychiatric symptoms, and movement disorders in schizophrenic patients.
    Newton JE; Cannon DJ; Couch L; Fody EP; McMillan DE; Metzer WS; Paige SR; Reid GM; Summers BN
    J Clin Psychiatry; 1989 Apr; 50(4):132-5. PubMed ID: 2925601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical implications of determination of plasma haloperidol levels.
    Santos JL; Cabranes JA; Almoguera I; Ramos JA; Vazquez C; Angeles F
    Acta Psychiatr Scand; 1989 Apr; 79(4):348-54. PubMed ID: 2735205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Psychopharmacol Bull; 1996; 32(1):75-9. PubMed ID: 8927679
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haloperidol blood levels during dosage reduction in chronic schizophrenic patients.
    Goldman Z; Ebstein RP; Lerer B; Zohar J; Hermoni M; Belmaker RH
    Neuropsychobiology; 1981; 7(6):281-4. PubMed ID: 7312145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects.
    Someya T; Muratake T; Hirokane G; Shibasaki M; Shimoda K; Takahashi S
    J Clin Psychopharmacol; 2000 Apr; 20(2):175-80. PubMed ID: 10770455
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A two-phase, double-blind randomized study of three haloperidol plasma levels for acute psychosis with reassignment of initial non-responders.
    Janicak PG; Javaid JI; Sharma RP; Leach A; Dowd S; Davis JM
    Acta Psychiatr Scand; 1997 Apr; 95(4):343-50. PubMed ID: 9150830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
    Balant-Gorgia AE; Eisele R; Balant L; Garrone G
    Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum haloperidol concentration and clinical response in schizophrenia.
    Kirch DG; Bigelow LB; Korpi ER; Wagner RL; Zalcman S; Wyatt RJ
    Schizophr Bull; 1988; 14(2):283-9. PubMed ID: 3201181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics.
    Gattaz WF; Rost W; Hübner CK; Bauer K
    Biol Psychiatry; 1989 Feb; 25(3):247-55. PubMed ID: 2643996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of propranolol treatment on serum prolactin level in schizophrenic patients.
    Elizur A; Segal Z; Yeret A; Ben-David M
    Commun Psychopharmacol; 1980; 4(3):203-6. PubMed ID: 7226751
    [No Abstract]   [Full Text] [Related]  

  • 38. Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.
    Hollister LE; Kim DY
    Am J Psychiatry; 1982 Nov; 139(11):1466-8. PubMed ID: 7137396
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting.
    Darby JK; Pasta DJ; Dabiri L; Clark L; Mosbacher D
    J Clin Psychopharmacol; 1995 Oct; 15(5):334-40. PubMed ID: 8830064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
    Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
    Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.